Consensus Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 16:55:00 05/12/2025 GMT			5-day change	1st Jan Change
85.00 ^EUR	+0.51%		-0.89%	-9.32%

12-05	SANOFI : Buy rating from Bernstein	ZD
12-05	Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns	RE

Evolution of the Average Target: Sanofi

Evolution of the Target Price: Sanofi

Changes in Analyst Recommendations: Sanofi

160d568297d0a2e2f1d8751ca0.WXv-1tNiOIOKcw3nplgl3KraWNF0i3u5JD86w5-c70U.PxCq7qRbV8n-P0Oe9Qtyi-2vHeY-zizcCW57lM3kgg44I6iCkStd6783Yg~90b7da5545b3228af6f4f30e9ad6c60f

Analysts' recommendations: Sanofi

12-05	SANOFI : Buy rating from Bernstein	ZD
11-25	SANOFI : Deutsche Bank reiterates its Buy rating	ZD
11-19	SANOFI : Buy rating from Jefferies	ZD
11-07	Sanofi Announces Positive Results from the pivotal LIBERTY- AFRS-AIMS Phase 3 Study	CI
11-07	Regeneron, Sanofi Say Dupixent for Allergic Fungal Rhinosinusitis Met Primary Endpoint in Phase 3 Study	MT
11-07	Sanofi, Regeneron's Dupixent Hits Key Goals in Late-Stage Fungal Allergy Trial	DJ
11-07	Sanofi's Dupixent Achieves Phase 3 Success in Allergic Fungal Rhinosinusitis
11-07	Sanofi and Regeneron's Dupixent meets endpoints, accepted for priority review by FDA	RE
11-07	Berenberg Upbeat on Sanofi's Top Line Growth, R&D Turnaround	MT
10-30	SANOFI : Deutsche Bank reaffirms its Buy rating	ZD
10-28	SANOFI : Goldman Sachs gives a Neutral rating	ZD
10-27	SANOFI : Deutsche Bank gives a Buy rating	ZD
10-27	UBS remains bullish on Sanofi after quarterly results.
10-27	SANOFI : Receives a Buy rating from Jefferies	ZD
10-27	SANOFI : UBS reiterates its Buy rating	ZD
10-24	SANOFI : DZ Bank keeps its Buy rating	ZD
10-24	SANOFI : Investors expect a home run now; earnings beat may not suffice
10-24	SANOFI : Receives a Buy rating from UBS	ZD
10-24	SANOFI : JP Morgan remains its Buy rating	ZD
10-24	SANOFI : Bernstein reiterates its Buy rating	ZD
10-24	SANOFI : Jefferies remains its Buy rating	ZD
10-22	SANOFI : JP Morgan reiterates its Buy rating	ZD
10-22	Sanofi's Efdoralprin Alfa met all primary and key secondary endpoints	RE
10-20	Sanofi's Tzield Accepts for Expanded Review in the US for Stage 3 Type 1 Diabetes Through FDA Commission's National Priority Voucher Pilot Program	CI
10-20	Sanofi's Application for Diabetes Drug Tzield Wins US FDA's Expedited Review	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SANOFI					+24.86%
	ELI LILLY AND COMPANY					+4.59%
	JOHNSON & JOHNSON					+0.74%
	ABBVIE INC.					+7.73%
	ROCHE HOLDING AG					+0.28%
	ASTRAZENECA PLC					+8.87%
	NOVARTIS AG					-1%
	MERCK & CO., INC.					+6.92%
	NOVO NORDISK A/S					+28.66%
	AMGEN INC.					-1.71%
	Average					+7.99%
	Weighted average by Cap.					+5.99%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

85.00EUR

Average target price

106.13EUR

Spread / Average Target

+24.86%

High Price Target

124.80EUR

Spread / Highest target

+46.82%

Low Price Target

95.00EUR

Spread / Lowest Target

+11.76%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BERNSTEIN RESEARCH	Florent Cespedes
JEFFERIES
GOLDMAN SACHS	James Quigley
alphavalue	Abhishek Raval
DZ BANK	Elmar Kraus
UBS	Matthew Weston
JPMORGAN	Richard Vosser
DEUTSCHE BANK RESEARCH	Emmanuel Papadakis
BERENBERG	Luisa Hector
Intron Health
Morgan Stanley
AlphaValue/Baader Europe
BARCLAYS	Emily Field
Berenberg Bank
CIC Market Solutions
STIFEL	Eric Le Berrigaud
CREDIT SUISSE	Dominic Lunn
Argus
Kepler Cheuvreux
DEUTSCHE BANK	Emmanuel Papadakis
Stifel Nicolaus
Liberum Capital
SVB Leerink
BAADER BANK
Deutsche Bank Securities
ODDO BHF
HSBC	Julie Mead
BANK OF AMERICA (BOFA)	Sachin Jain